Pimonidazole (Synonyms: NSC 380540, Ro 038799) |
| Katalog-Nr.GC41338 |
Pimonidazol ist ein neuartiger Hypoxie-Marker zur ergÄnzenden Untersuchung von Tumorhypoxie und Zellproliferation im Tumor. Pimonidazol reichert sich in hypoxischen Zellen durch kovalente Bindung mit MakromolekÜlen oder durch Bildung reduktiver Metaboliten nach Reduktion seiner Nitrogruppe an und kann zur qualitativen und quantitativen Beurteilung von Tumorhypoxie verwendet werden .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 70132-50-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Hypoxic cells are low oxygen cells that when present in tumors are radioresistant and chemoresistant. Pimonidazole is a small molecule radiosensitizer that has proven to be an effective and nontoxic hypoxia marker for human squamous cell carcinomas of the cervix, head, and neck.[1] This immunochemical hypoxia marker has been widely used in experimental and clinical studies due to its chemical stability, water solubility, and wide tissue distribution. It is generally administered in aqueous solution by injection.
Reference:
[1]. Kaanders, J.H.A.M., Wijffels, K.I.E.M., Marres, H.A.M., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Research 62, 7066-7074 (2002).
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *